Healthcare Industry News: neuroradiology
News Release - July 23, 2009
Micrus Endovascular Announces Positive DeltaPaq Microcoil Study ResultsSAN JOSE, Calif.--(HSMN NewsFeed)--Micrus Endovascular Corporation (NASDAQ:MEND ) today announced that study results presented recently at the 10th Congress of the World Federation of Interventional and Therapeutic neuroradiology (WFITN) demonstrated that the DeltaPaq™ microcoil’s proprietary design appears to improve the uniformity of coil distribution within a cerebral aneurysm and the degree of microcoil packing in the aneurysm dome and neck, which may reduce the risk of aneurysm recurrence. Bernard R. Bendok, M.D., Assistant Professor of Neurological Surgery and Radiology, Department of Neurological Surgery of Northwestern University Feinberg School of Medicine, and Matthew Gounis, Ph.D., Director of the New England Center for Stroke Research at the University of Massachusetts, served as principal investigators for the Micrus-sponsored in vitro study.
“The objective of this study was to assess whether the type of coil used had an impact on packing density and coil distribution within an aneurysm,” said Dr. Bendok. “Conventional thinking has been that higher packing density reduces coil compaction and therefore leads to fewer retreatments. This study suggests that the DeltaPaq microcoil may improve uniformity of coil distribution and demonstrated that DeltaPaq had a statistically significant greater packing density compared with traditional helical and complex coil designs. This is the first study to examine coil distribution in different sections of an aneurysm. Uniformity of distribution, which was found to be superior with DeltaPaq, is a possible predictor of treatment durability.”
Ron Benitez, M.D., of the Atlantic Neurosciences Institute, Overlook Hospital in Summit, NJ, commented, “In general, my personal experience is that with Cerecyte® coils I see better outcomes than I did when using bare platinum coils. My approach today is to frame with one or two Presidio Cerecyte® or MicruSphere® coils, followed almost exclusively by DeltaPaq Cerecyte coils. The DeltaPaq coil is more conformable than other filling coils and therefore able to better find open voids in the aneurysm, leading to a more complete packing or filling of the aneurysm. I believe that the combination of Cerecyte with DeltaPaq’s filling capabilities will undoubtedly lead to a further reduction in my recanalization and retreatment rates.”
“We are singularly focused on developing and commercializing innovative products for the neurointerventional market,” said John Kilcoyne, Chairman and CEO of Micrus Endovascular. “Our DeltaPaq features a completely new coil technology we call 'Delta Wind,' which was designed to improve the interventionalist’s ability to more thoroughly fill aneurysms. The market has responded very positively to DeltaPaq, which represented 13% of our revenues in our most recently reported quarter. We are equally excited about our DeltaPlush™ extra-soft, stretch-resistant finishing coil, also based on our Delta Wind technology, which we plan to launch later this fiscal year.”
About Micrus Endovascular Corporation
Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus’ proprietary, three-dimensional microcoils automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils. For more information, visit www.micruscorp.com.
Micrus, from time to time, may discuss forward-looking information, including estimated fiscal 2010 revenues. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include the risk of inconclusive or unfavorable clinical trial results, the Company’s ability to obtain, and the timing of, regulatory approvals and clearances for its products, product enhancements or future products, and other risks affecting the Company, including the Company’s limited operating history and history of significant operating losses, fluctuations in quarterly operating results, which are difficult to predict, currency exchange rate fluctuations, the Company’s dependence on developing new products or product enhancements, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing Micrus’ relationships with physicians and other consultants, the Company’s ability to compete with large, well-established medical device manufacturers with significant resources and other risks as detailed from time to time in risk factors and other disclosures in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2009, and other filings with the Securities and Exchange Commission. All forward-looking statements in this release represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intention or obligation to update forward-looking statements.
Source: Micrus Endovascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.